Table II.
Laboratory markers in intensive care unit (ICU) patients with coronavirus disease 2019 (COVID-19) (January–December 2021)
| COVID-19-positive ICU patients |
||
|---|---|---|
| Tocilizumab | No tocilizumab | |
| N | 41 | 33 |
| CRP (mg/L) | ||
| Median | 96 | 130 |
| Range | 2–283 | 6–319 |
| Ferritin (ng/mL) | ||
| Median | 843 | 830 |
| Range | 14–4745a | 54–2856b |
| D-dimer (μg/mL) | ||
| Median | 1.76 | 2.45 |
| Range | 0.4–4.0 | 0.36–4.0c |
| IL-6 (ng/L) | ||
| Median | 36 | 67 |
| Range | 3–3770 | 8–50,000 |
| White cell count (x 109/L) | ||
| Median | 9.66 | 9.25 |
| Range | 2.57–327 | 2.77–33.04 |
| Lymphocytes (x 109/L) | ||
| Median | 0.53 | 0.68 |
| Range | 0.21–284 | 0.32–5.9 |
| Procalcitonin (μg/L) | ||
| Median | 0.26 | 0.25 |
| Range | 0.06–1.88d | 0.06–100e |
CRP, C-reactive protein; IL-6, interleukin-6.
a
Data from 35/41 patients.
b
Data from 31/33 patients.
c
Data from 32/33 patients.
d
Data from 37/41 patients.
e
Data from 30/33 patients.